| 3.02 0.05 (1.68%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.66 | 1-year : | 7.29 |
| Resists | First : | 4.84 | Second : | 6.25 |
| Pivot price | 3.72  |
|||
| Supports | First : | 2.57 | Second : | 2.14 |
| MAs | MA(5) : | 2.92 |
MA(20) : | 3.7 |
| MA(100) : | 3.2  |
MA(250) : | 2.92 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.5 |
D(3) : | 7.3 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 6.9 | Low : | 1.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CELZ ] has closed above bottom band by 29.3%. Bollinger Bands are 239.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.29 - 3.3 | 3.3 - 3.32 |
| Low: | 2.9 - 2.92 | 2.92 - 2.94 |
| Close: | 2.99 - 3.02 | 3.02 - 3.05 |
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Wed, 05 Nov 2025
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now - Nasdaq
Fri, 31 Oct 2025
Market Sentiment Around Loss-Making Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) - Yahoo Finance
Thu, 30 Oct 2025
Creative Medical (NASDAQ: CELZ) launches Veterans BioDefense; Greenstone to power AI - Stock Titan
Mon, 27 Oct 2025
Creative Medical Technology Holdings, Inc. Reports 2025 Milestones and Strategic Advancements in Regenerative Medicine - Quiver Quantitative
Mon, 27 Oct 2025
Creative Medical Technology’s CELZ-201: A Promising Step in Diabetes Treatment - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.18e+006 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.81e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -98 % |
| Return on Assets (ttm) | 656.7 % |
| Return on Equity (ttm) | -49.1 % |
| Qtrly Rev. Growth | 6000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -15.3 |
| EBITDA (p.s.) | 689.65 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.2 |
| Price to Cash Flow | 5.94 |
| Dividend | 0 |
| Forward Dividend | 52200 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|